Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia 2009

Economic evaluation of NSPs in the Australian Capital Territory

Page last updated: 2009

The spending of $8.8m in the funding of NSPs in the Australian Capital Territory from year 2000-2009 has resulted in a saving of $11.5m in healthcare costs, with more than 2,000 Disability Adjusted Life Years saved, with a net financial saving of $2.6m. A summary of the return on investment of NSP funding in the Australian Capital Territory is shown in Table 16. The mathematical and economic modelling estimated that if NSPs are continued at the same level of funding in the Australian Capital Territory for the next ten years, $4.9m of net financial savings will accrue ($4.36m discounted at 3%) and for twenty years $10.6m ($8.01m discounted at 3%). The lifetime net present value of investment in NSPs that took account of all healthcare costs and savings (but not costs associated with productivity losses) would be $293m ($65.9m discounted at 3%).

Table 16: Return on investment of NSP funding in the Australian Capital Territory (2000-2009)

2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Healthcare costs saved $m
(IQR)
1.1
(0.9-1.2)
0.6
(0.5-0.7)
0.6
(0.5-0.7)
0.9
(0.8-1.0)
1.2
(1.1-1.3)
1.3
(1.2-1.4)
1.3
(1.2-1.5)
1.4
(1.3-1.6)
1.5
(1.4-1.7)
1.6
(1.4-1.7)
NSP funding $m (median)
0.6
0.6
0.8
0.7
0.8
0.8
0.9
1.2
1.2
1.2
Net cost savings $m (median)
0.4
0.04
0.1
0.2
0.4
0.5
0.4
0.2
0.3
0.3
DALY gain (median)
206
199
182
171
171
181
196
210
222
234

Please note that any inconsistencies between the figures presented in the above text and table are due to rounding. Additionally, the results for each jurisdiction are provided to assist in assessment of local return on investment. The small numbers in some jurisdictions may distort parameter uncertainties and should not be used to compare one jurisdiction with another.


Top of page